A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab MK-3475, NSC 776864 in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase II, Open-label, Randomized, Two-stage Clinical Study
of Alvocidib in Patients with Relapsed/Refractory Acute
Myeloid Leukemia Following Treatment with Venetoclax
Combination Therapy
An Open-label, Multicenter, Phase II Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non?Small-Cell Lung Cancer NSCLC Without Actionable Genomic Alterations.
A Phase III Randomized, Open-Label Study of Optune Ttfields, 200KHZ Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation PREDICT-RT
A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3K Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
A Randomized Phase III Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide VINO-AC Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide VINO-CPO vs Vincristine, Dactinomycin and Cyclophosphamide VAC plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma HR-RMS
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma RRMM Who Have Normal and Varying Degrees of Impaired Renal Function DREAMM 12